ArticleGlobal health & medicine2023
Four decades of continuing innovations in the development of antiretroviral therapy for HIV/AIDS: Progress to date and future challenges.
Article in Global health & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Systematic Literature Review and Meta-Analysis of INSTI-Based Antiretroviral Therapy Single- Versus Multiple-Tablet Regimens for the Treatment of HIV.Advances in therapy · 2026Pooled it
- The effect of emotional freedom techniques on anxiety depression and sleep in older people living with HIV: a randomized controlled trial.AIDS research and therapy · 2024Trial
- 1,3,4-Oxadiazole-sulfonamide hybrids: recent advances in biological activities, structure-activity relationships, and therapeutic applications.RSC advances · 2026Review
- HIV Burden Trends in Kyrgyzstan, 1990-2025: A National Analysis of GBD 2021 Estimates and Short-Term Projections.Health science reports · 2026Article
- Phylogenetic Evidence of Local HIV-1 Transmission and Antiretroviral Drug Resistance in the Middle East and North Africa.Viruses · 2026Article
- Pretreatment HIV-1 drug resistance and molecular subtype characteristics among newly diagnosed individuals in Guangxi, China.AIDS research and therapy · 2026Article
- Life expectancy of people with hemophilia in France in 2022.European journal of epidemiology · 2026Article
- Computational design, synthesis and biological evaluation of novel pyridinone derivatives as NNRTIs.Scientific reports · 2026Article
- Immune checkpoint landscape in CD4⁺ T cells stratifies HIV-infected individuals by clinical progression.Immunologic research · 2026Article
- Next-Generation HIV-1 Therapeutics in Co-Endemic Settings.Biomedicines · 2026Review
- Mental Health and ART Adherence in a Multisite International Study: The Mediating Roles of Social Support and Substance Use in People with HIV.AIDS and behavior · 2026Article
- Redefining pandemic resilience: a roadmap for post-infectious syndrome preparedness and health system transformation.Frontiers in health services · 2026Article
- The Future of Newly Diagnosed HIV Cases in Iran Through 2030: A Mixed-Methods Trend Impact Analysis.HIV/AIDS (Auckland, N.Z.) · 2026Article
- Do men face greater barriers to accessing HIV testing services than women? Might HIV self-testing be the answer? Evidence from a longitudinal survey in east Zimbabwe (2018-2023).PLOS global public health · 2026Article
- Enhanced TLR7-induced interferon responses in women living with HIV.Frontiers in immunology · 2026Article
- Co-amorphous Approach for Enhancing Rilpivirine Oral Bioavailability using CYP3A4 Inhibitor as a Co-former.AAPS PharmSciTech · 2025Article
- Novel approach in HIV therapy: lipid nanoparticle-based mRNA delivery technology using LNP X-HIV Tat-CRISPRa system.Advanced pharmaceutical bulletin · 2025Article
- Article
- The contribution of TB rapid diagnostic testing in reducing TB-related mortality in Sub-Saharan Africa- in both Person-Living with HIV and HIV-Negative populations: A 9-year quantitative retrospective analysis.BMC infectious diseases · 2025Article
- From Management to Cure: The Shifting Paradigm in HIV and Chronic Viral Hepatitis.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The treatment of HIV-1 infection and AIDS represents one of the greatest challenges in medicine. While there is no cure for HIV/AIDS, truly remarkable progress has been made for treatment of HIV/AIDS patients today. The advent of combination antiretroviral therapy (cART) in the mid-1990s dramatically improved HIV-1 related morbidity, greatly prolonged life expectancy, and delayed progression of AIDS. Due to current antiretroviral therapy, the mortality rate for HIV infected patients is closely approaching the mortality rate for the general population. The long-term success of HIV-AIDS treatment requires continued enhancement of cART with further development of novel drugs that would exhibit fewer side effects, higher genetic barrier to the development of resistance, and longer action with durable virologic suppression. This editorial article provides a quick review of four decades of intense drug development research efforts targeting various viral enzymes and cellular host factors leading to the evolution of today's treatment of patients with HIV-1 infection and AIDS. It also touches on challenges of future treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.